NASDAQ: CSBRChampions Oncology Inc Stock
$5.30-0.15 (-2.75%)
Updated Aug 5, 2026
CSBR Price
$5.30
Fair Value Price
$0.09
Market Cap
$73.64M
52 Week Low
$5.20
52 Week High
$8.74
P/E
-66.25x
P/B
18.69x
P/S
1.39x
PEG
N/A
Dividend Yield
N/A
Revenue
$59.43M
Earnings
-$1.18M
Gross Margin
48%
Operating Margin
-1.56%
Profit Margin
-2%
Debt to Equity
5.82
Operating Cash Flow
-$4M
Beta
0.35
Next Earnings
Sep 21, 2026
Ex-Dividend
N/A
Next Dividend
N/A
CSBR Overview
Champions Oncology, Inc. is dedicated to developing and commercializing cutting-edge technological products and services designed to personalize cancer treatment and streamline the development of oncology drugs across the United States. At the heart of its offerings is the Tumorgraft Technology Platform, an innovative approach that facilitates individualized cancer care by implanting human tumors into immune-deficient mice. Utilizing this proprietary platform, the company not only delivers personalized cancer solutions directly but also provides Translational Oncology Solutions, supporting pharmaceutical and biotechnology companies through their drug development lifecycle. Additionally, Champions Oncology offers Lumin Bioinformatics, a comprehensive software platform and data tool filled with insights from research services and clinical studies, accessible through annual subscriptions. The company distributes its offerings through various channels, including online platforms, word-of-mouth referrals, and a dedicated sales team, reaching both patients and healthcare professionals. Established in 1985, Champions Oncology, Inc. is based in Hackensack, New Jersey, and was formerly known as Champions Biotechnology, Inc. until its name change in April 2011.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine CSBR's potential to beat the market
- CSBR doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
CSBR
RankedUnranked of 465
RankedUnranked of 465
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $10.75 | A | |
| $110.69 | A | |
| $8.11 | A |
Be the first to know about important CSBR news, forecast changes, insider trades & much more!
CSBR News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how CSBR scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
CSBR ($5.30) is overvalued by 6,003.43% relative to our estimate of its Fair Value price of $0.09 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
CSBR ($5.30) is not significantly undervalued (6,003.43%) relative to our estimate of its Fair Value price of $0.09 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
CSBR is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more CSBR due diligence checks available for Premium users.
Valuation
CSBR fair value
Fair Value of CSBR stock based on Discounted Cash Flow (DCF)
Price
$5.30
Fair Value
$0.09
Overvalued by
6,003.43%
CSBR ($5.30) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
CSBR ($5.30) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
CSBR is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
CSBR price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-66.25x
Industry
14.89x
Market
14.23x
CSBR price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
18.69x
Industry
5.31x
CSBR is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
CSBR's financial health
Profit margin
Revenue
$13.8M
Net Income
-$667.0k
Profit Margin
-4.8%
CSBR's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
CSBR's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$27.0M
Liabilities
$22.9M
Debt to equity
5.82
CSBR's short-term liabilities ($19.92M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CSBR's short-term assets ($19.22M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CSBR's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
CSBR's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$2.0M
Investing
-$238.0k
Financing
-$19.0k
CSBR's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
CSBR vs Biotech Stocks
Champions Oncology Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.